Stiles Financial Services Inc Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Stiles Financial Services Inc lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,432 shares of the biopharmaceutical company’s stock after buying an additional 89 shares during the quarter. Regeneron Pharmaceuticals makes up approximately 1.3% of Stiles Financial Services Inc’s portfolio, making the stock its 17th biggest holding. Stiles Financial Services Inc’s holdings in Regeneron Pharmaceuticals were worth $3,606,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of REGN. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Sachetta LLC grew its position in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $28,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Finally, Family Firm Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $827.00 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a one year low of $783.57 and a one year high of $1,211.20. The company has a 50-day simple moving average of $1,035.92 and a two-hundred day simple moving average of $1,038.36. The firm has a market capitalization of $91.17 billion, a PE ratio of 20.40, a price-to-earnings-growth ratio of 3.17 and a beta of 0.15.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 7.48% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on REGN. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.